Аrgon-oxygen breathing mixture

Phase 3Small molecule

NNegovsky Reanimatology Research Institute

Аrgon-oxygen breathing mixture is one of 7 small molecule programs targeting Recovery. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RecoveryRecruiting

RecoveryPhase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Recovery

#DrugCompanyPhaseTrials

N-Acetyl-L-Cysteine

PPeking University People's Hospital

Phase 2

1 2

Аrgon-oxygen breathing mixture

NNegovsky Reanimatology Research Institute

Phase 3

1 3

BXCL501

BBioXcel Therapeutics Inc

Phase 2

1 4

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 5

Bupivacaine-Fentanyl

SSamuel Lunenfeld Research Institute, Mount Sinai Hospital

Preclinical

1 6

Dual NRT

MMassachusetts General Hospital

Preclinical

1 7

L-Tyrosine

DDirection Centrale du Service de Santé des Armées

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recovery1 trial

Perioperative Argon Inhalation to Improve Neurocognitive Recovery After Carotid Surgery

Recruiting·NNegovsky Reanimatology Research Institute·Phase 3·NCT07200180·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Аrgon-oxygen breathing mixture. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Аrgon-oxygen breathing mixture compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Аrgon-oxygen breathing mixture. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Negovsky Reanimatology Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNegovsky Reanimatology Research Institute

Аrgon-oxygen breathing mixture

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recovery1 trial

References

Drug Info

Quick Facts

Related News